RECRUITING

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Conditions

Adenocarcinoma of Lung NOVOTTF-200T system TTFields treatment 22-387

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.

Official Title

A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients With Early-Stage Resectable Lung Adenocarcinoma

Quick Facts

Study Start:2023-08-04

Study Completion:2027-08

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05764954

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study. * The participant is ≥22 years of age on the day of signing informed consent. * The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection. * The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy. * The participant with multiple nodules has one nodule that meets the criteria. * The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.	* Patients receiving therapy for concurrent active malignancy * Patients with a history of cardiac arrhythmias and/or pacemaker use * Patients with lung nodules \<1cm * Patients with lung nodules that are pure ground glass opacities (GGOs) of any size * Patients with lung nodules that are \<50% solid of any size

Inclusion Criteria

Exclusion Criteria

* The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study.
* The participant is ≥22 years of age on the day of signing informed consent.
* The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection.
* The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy.
* The participant with multiple nodules has one nodule that meets the criteria.
* The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.

* Patients receiving therapy for concurrent active malignancy
* Patients with a history of cardiac arrhythmias and/or pacemaker use
* Patients with lung nodules \<1cm
* Patients with lung nodules that are pure ground glass opacities (GGOs) of any size
* Patients with lung nodules that are \<50% solid of any size

Contacts and Locations

Study Contact

Prasad Adusumilli, MD

CONTACT

212-639-8093

adusumip@mskcc.org

Matthew Bott, MD

CONTACT

212-639-5944

Principal Investigator

Prasad Adusumilli, MD

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Basking Ridge (Consent Only)

Basking Ridge, New Jersey, 07920

United States

Memorial Sloan Kettering Monmouth (Consent Only)

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen (Consent Only)

Montvale, New Jersey, 07645

United States

Memorial Sloan Kettering Suffolk - Commack (Consent Only)

Commack, New York, 11725

United States

Memorial Sloan Kettering Westchester (Consent Only)

Harrison, New York, 10604

United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065

United States

Memorial Sloan Kettering Nassau (Consent Only)

Uniondale, New York, 11553

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Prasad Adusumilli, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-08-04

Study Completion Date2027-08

Study Record Updates

Study Start Date2023-08-04

Study Completion Date2027-08

Terms related to this study

Keywords Provided by Researchers

NOVOTTF-200T system
TTFields treatment
22-387

Additional Relevant MeSH Terms

Adenocarcinoma of Lung